Chronic lymphocytic leukaemia: The nature of the leukaemic cell

Blood Reviews

Volumn 11, Issue 3, 1997, Pages 119-128

  Hamblin, T J ^a   Oscier, D G ^a  

^a ROYAL BOURNEMOUTH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD5 ANTIGEN; CELL ADHESION MOLECULE; CELL SURFACE MARKER; CYTOKINE; LYMPHOCYTE ANTIGEN; LYMPHOCYTE MEMBRANE IMMUNOGLOBULIN; PROTEIN P53; TUMOR ANTIGEN;

B LYMPHOCYTE; CANCER GENETICS; CELL CYCLE; CELL CYCLE G0 PHASE; CELL STRUCTURE; CHROMOSOME 11Q; CHROMOSOME 12; CHROMOSOME 13; CHROMOSOME 14Q; CHROMOSOME ABERRATION; CHRONIC LYMPHATIC LEUKEMIA; HUMAN; IMMUNOPHENOTYPING; LEUKEMIA CELL; LYMPHOCYTE ACTIVATION; LYMPHOCYTE PROLIFERATION; PRIORITY JOURNAL; REVIEW; TRISOMY; TUMOR SUPPRESSOR GENE;

EID: 0030722666     PISSN: 0268960X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0268-960X(97)90007-2     Document Type: Article

References (123)

1. Matutes E, Oscier D, Garcia-Marco J et al. Trisomy 12 defines a group of CLL with atypical morphology: correlation between cytogenetic, clinical and laboratory features in 544 patients. Br J Haematol 1996; 92: 382-388.
2. Rozman C, Hernandez-Nieto L, Montserrat E, Brugues R. Prognostic significance of bone marrow patterns in chronic lymphocytic leukaemia. Br J Haematol 1981; 47: 529-537.
3. Andreeff M, Danzyrkiewicz Z, Sharpless TK, Clarkson BD, Melamed MR. Discrimination of human leukemia subtypes by flow cytometric analysis of cellular DNA and RNA. Blood 1980; 55: 282-293.
4. Orchard JA, Oscier DG. Prognostic value of Ki 67 and cell cycle analysis in chronic lymphocytic leukaemia. Br J Haematol 1996; 93 (suppl 2): 116.
5. Delmer A, Ajchenbaum-Cymbalista F, Tang R et al. Overexpression of Cyclin D2 in chronic B-cell malignancies. Blood 1995; 85: 2870-2876.
6. Okamura J, Gelfand EW, Letarte M. Heterogeneity of the response of chronic lymphocytic leukemia cells to phorbol ester. Blood 1982; 60: 1082-1088.
7. Malisan F, Fluckiger A-C, Ho S, Guret C, Banchereau J, Martinez-Valdez H. B-chronic lymphocytic leukemias can undergo isotype switching in vivo and can be induced to differentiate and switch in vitro. Blood 1996; 87: 717-724.
8. Dono M, Hashimoto S, Fais F et al. Evidence for progenitors of chronic lymphocytic leukemia B cells that undergo intraclonal differentiation and diversification. Blood 1996; 87: 1586-1594.
9. Hoffbrand AV, Panayiotidis, Reittie J, Ganeshaguru K. Autocrine and paracrine growth loops in chronic lymphocytic leukemia. Semin Haematol 1993; 30: 306-317.
10. di Celle PF, Carbone A, Marchis D et al. Cytokine gene expression in B-cell chronic lymphocytic leukemia: evidence of constitutive Interleukin-8 (IL-8) mRNA expression and secretion of biologically active IL-8 protein. Blood 1994; 84: 220-228.
11. Lotz M, Ranheim E, Kipps TJ. Transforming growth factor beta as endogenous growth inhibitor of chronic lymphocytic leukemia B cells. J Exp Med 1994; 179: 999-1004.
12. Panayiotidis P, Jones D, Ganeshaguru K, Foroni L, Hoffbrand AV. Human bone marrow stromal cells prevent apoptosis and support the survival of chronic lymphocytic leukaemia cells in vitro. Br J Haematol 1996; 92: 97-103.
13. Mainou-Fowler T, Craig VA, Copplestone JA, Hamon MD, Prentice AG. Interleukin-5 (IL-5) increases spontaneous apoptosis of B-cell chronic lymphocytic leukemia cells in vitro independently of bcl-2 expression, and is inhibited by IL-4 Blood 1994; 84: 2297-2304.
14. Fluckiger AC, Rossi JF, Bussel A, Bryon P, Banchereau J, Defrance T. Responsiveness of chronic lymphocytic leukemia B cells activated via surface Igs or CD40 to B-cell tropic factors. Blood 1992; 80: 3173-3181.
15. Ternynck T, Diaghiero G, Fallezou J, Binet JL. Comparison of normal and CLL lymphocyte surface Ig determinants using peroxidase-labelled antibodies. I. Detection and quantitation of light chain determinants. Blood 1974; 43: 789-795.
16. Hamblin TJ, Hough D. Chronic lymphatic leukaemia: correlation of immunofluorescent characteristic with clinical features. Br J Haematol 1977; 36: 359-365.
17. Stevenson FK, Hamblin TJ, Stevenson GT. The nature of IgG on the surface of B lymphocytes in chronic lymphocytic leukemia. J Exp Med 1981; 154: 1965-1969.
18. Hashimoto S, Dono M, Watai M et al. Somatic diversification and selection of IgH and L chains variable region genes in IgG+, CD5+ chronic lymphocytic leukemia B cells. J Exp Med 1995; 181: 1507-1517.
19. Fais F, Sellars B, Ghiotto F et al. Examples of in vivo isotype class switching in IgM (+) chronic lymphocytic leukemia cells. J Clin Invest 1996; 98: 1659-1666.
20. Slease RB, Wistar R Jr, Scher I. Surface immunoglobulin density in human peripheral blood mononuclear cells. Blood 1979; 54: 72-87.
21. Fermand JP, Schmitt C, Brouet JC. Distribution of class II DC antigens on normal and leukaemic lymphoid cells. Eur J Immunol 1985; 15: 1183-1187.
22. Freedman AS, Boyd AW, Berrebi A et al. Expression of B cell activation antigens on normal and malignant B cells. Leukemia 1987; 1: 9-15.
23. Anderson KC, Bates MP, Slaughenhaupt BL et al. Expression of human B cell associated antigens on leukaemias and lymphomas: a model of B cell differentiation. Blood 1984; 63: 1424-1431.
24. Freedman AS, Nadler LM. Immunologic markers in B-cell chronic lymphocytic leukemia. In: Cheson BD, ed. Chronic Lymphocytic Leukemia: Scientific Advances and Clinical Developments. New York: Marcel Dekker, 1993: 1-32.
25. Catovsky D, Cherchi M, Okos A, Hegde V, Galton DAG. Mouse red cell rosettes in B lymphoproliferative disorders. Br J Haematol 1976; 33: 173-177.
26. Foon KA, Schroff RW, Gale RP. Surface markers on leukaemia and lymphoma cells. Blood 1982; 60: 1-19.
27. Bain BJ, Catovsky D. The leukaemic phase of non-Hodgkin's lymphoma. J Clin Pathol 1995; 48: 189-193.
28. Matutes E, Owusu-Ankomah K, Morilla R et al. The immunological profile of B-cell disorders and proposal of a scoring system for the diagnosis of CLL. Leukemia 1994; 8: 1640-1645.
29. Caligaris-Cappio F, Gobbi M, Bergui L et al. B chronic lymphocytic leukemia patients with stable benign disease show a distinctive membrane phenotype. Br J Haematol 1984; 56: 655-660.
30. Catovsky D, Cherchi M, Brooks J, Bradley J, Zola H. Heterogeneity of B cell leukemias demonstrated by the monoclonal antibody FMC7. Blood 1981; 33: 173-177.
31. Delia D, Cattoretti G, Polli N et al. CD1c but neither CD1a nor CD1b molecules are expressed on normal, activated and malignant B cells. Identification of a new B cell subset. Blood 1988; 72: 241-247.
32. Orazi A, Cattoretti G, Polli N, Rilke F. Distinct morphophenotypic features of chronic B lymphocytic leukemia identified with CD1c and CD23 antibodies. Eur J Haematol 1991; 47: 28-35.
33. Freedman AS, Boyd AW, Bieber F et al. Normal cellular counterparts of B cell chronic lymphocytic leukemia. Blood 1987; 70: 418-427.
34. Zomas AP, Matutes E, Morilla R, Owusu-Ankomah K, Seon BK, Catovsky D. Expression of the immunoglobulin-associated protein B29 in B cell disorders with the monoclonal antibody SN8 (CD79b). Leukemia 1996, 10: 1966.
35. Inghirami G, Wieczorek R, Zhu B, Silber R, Della-Favera R, Knowles DM. Differential expression of LFA-1 molecules in non-Hodgkin's lymphoma and lymphoid leukemias. Blood 1988; 72: 1431-1434.
36. Maio M, Pinto A, Carbone A et al. Differential expression of CD54/intercellular adhesion molecule-1 in myeloid leukemias and in lymproliferative disorders. Blood 1990; 76: 783-790.
37. Wormsley S, Baird S, Gadol N, Rai K, Sobal R. Characteristics of CD11c+CD5+ chronic B-cell leukemias and the identification of normal peripheral blood B-cell subsets with chronic lymphoid leukemia immunophenotypes. Blood 1990; 76: 123-130.
38. Csanaky G, Vass JA, Miloserits J, Ocsovszki I, Szornor A, Schirelczerm M. Expression and function of L selectin molecules (Lecam-1) in B-cell chronic lymphocytic leukemia. Haematologica 1994; 79: 132-136.
39. Picker LJ, Medeiros LJ, Weiss LM, Warnke RA, Butcher EC. Expression of lymphocyte having receptor antigen in non-Hodgkin's lymphoma. Am J Pathol 1988; 130: 496-504.
40. Hynes RO. Integrins: versatility, modulation and signalling in cell adhesion. Cell 1992; 69: 11-25.
41. Hemler ME. VLA proteins in the integrin family: structures, functions and their role on leukocytes. Ann Rev Immunol 1990; 8: 365-400.
42. Moller P, Eichelman A, Konetz K, Mechtersheimer G. Adhesion molecules VLA-1 to VLA-6 define discrete stages of peripheral B lymphocyte development and characterize different types of B cell neoplasia. Leukemia 1992; 6: 256-264.
43. Vincent AM. Adhesion mechanisms in CLL and HCL. PhD thesis. University of Liverpool, 1996.
44. Baldini LGM, Cro LM. Structure and function of VLA integrins: differential expression in B cell leukemia/lymphoma. Leuk Lymphoma 1994; 12: 197-203.
45. Andrew DP, Berlin C, Honda J et al. Distinct but overlapping epitopes are involved in α4β7 mediated adhesion to vascular cell adhesion molecule-1 mucosal adhesion-1, fibronectin and lymphocyte aggregation. J Immunol 1994; 153: 3847-3861.
46. Gordon J, Mellstedt H, Arman P, Biberefield P, Bjorkholm M, Klein G. Phenotypes in chronic B-lymphocytic leukemia probed by monoclonal antibodies and immunoglobulin secretion studies: identification of stages of maturation arrest and the relation to clinical findings. Blood 1983; 62: 910-917.
47. Lewandrowski K, Medeiros L, Harris N. Expression of the activation antigen. 4F2, by non-Hodgkin's lymphomas of B-cell phenotype. Cancer 1990; 66: 1158-1164.
48. Karrag S, Leprence C, Merle-Beral H, Debre P, Richard Y, Galanaud P. B8.7 antigen expression on B-CLL cells and its relationship to the LMW-BCGF responsiveness. Leuk Res 1990; 14: 809-814.
49. Gahrton G, Zech L, Robert K-H, Bird AG. Mitogenic stimulation of leukemic cells by Epstein-Barr virus. N Engl J Med 1979; 301: 438.
50. Oscier DG. Cytogenetic and molecular abnormalities in chronic lymphocytic leukaemia. Blood Reviews 1994; 8: 88-97.
51. Gahrton G, Robert K-H, Friberg K, Zech L, Bird AG. Nonrandom chromosomal aberrations in chronic lymphocytic leukemia revealed by polyclonal B-cell stimulation. Blood 1980; 56: 640-647.
52. Han T, Ozer H, Sadamori N et al. Prognostic importance of cytogenetic abnormalities in patients with chronic lymphocytic leukemia. N Engl J Med 1984; 310: 288-292.
53. Pittman S, Catovsky D. Prognostic significance of chromosomal abnormalities in chronic lymphocytic leukaemia. Br J Haematol 1984; 58: 649-660.
54. Fitchett M, Griffiths MJ, Oscier DG, Johnson S, Seabright M. Chromosome abnormalities involving band 13q14 in hematologic malignancies. Cancer Genet Cytogenet 1987; 24: 143-150.
55. Juliusson G, Oscier DG, Fitchett M et al. Prognostic subgroups in B-cell chronic lymphocytic leukemia defined by specific chromosomal abnormalities. N Engl J Med 1990; 323: 720-724.
56. Geisler CH, Philip P, Hansen MM. B-cell chronic lymphocytic leukaemia: clonal chromosomal abnormalities and prognosis in 89 cases. Eur J Haematol 1989; 43: 397-403.
57. Bird ML, Ueshima Y, Rowley JD, Haren JM, Vardiman JW. Chromosomal abnormalities in B cell chronic lymphocytic leukemia and their clinical correlations. Leukemia 1989; 3: 182-191.
58. Oscier DG, Fitchett M, Hamblin TJ. Chromosomal abnormalities in B-CLL. Nouv Rev Fr Hematol 1988; 30: 397-398.
59. Petersen LC, Lindquist L, Church S, Kay NE. Frequent clonal abnormalities of chromosome band 13q14 in B cell chronic lymphocytic leukemia. Multiple clones, subclones and nonclonal alterations in 82 mid-western patients. Genes Chromosomes Cancer 1992; 4: 273-280.
60. Döhner H, Stilgenbauer S, Liebisch P et al. 11q deletions are the second most common chromosome aberration in B-cell chronic lymphocytic leukemia and are associated with advanced stages and marked lymphadenopathy. Blood 1995; 86: (suppl.1): 1369a.
61. Offit K, Parsa NL, Gaidano G et al. 6q deletions define distinct clinico-pathologic subsets of non-Hodgkin's lymphoma. Blood 1993; 82: 2157-2162.
62. Que TH, Marco G, Ellis J et al. Trisomy 12 in chronic lymphocytic leukemia detected by fluorescence in situ hybridisation: analysis by stage, immunophenotype and morphology. Blood 1993; 82: 571-575.
63. Oscier D, Fitchett M, Herbert T, Lambert R. Karyotypic evolution in B-cell chronic lymphocytic leukaemia. Genes Chromosomes Cancer 1991; 3: 16-20.
64. Einhorn S, Burvall K, Juliusson G, Gahrton G, Meeker T. Molecular analyses of chromosome 12 in chronic lymphocytic leukemia. Leukemia 1989; 3: 871-874.
65. Garcia-Marco J, Matutes E, Morilla R et al. Trisomy 12 in B-cell chronic lymphocytic leukaemia: assessment of lineage restriction by simultaneous analysis of immunophenotype and genotype in interphase cells by fluorescence in situ hybridization. Br J Haematol 1994; 83: 44-50.
66. Oscier DG, Copplestone JA, Chapman R et al. Atypical lymphocyte morphology and abnormal karyotype predict disease progression in stage A and A0 chronic lymphocytic leukaemia. Blood 1994; 84 (suppl 1): 452a.
67. Oscier DG, Chapman R, Cowell J. Deletion of a retinoblastoma gene in B cell chronic lymphocytic leukaemia. Blood 1990; 76: 241a.
68. Liu Y, Szekely L, Grander D et al. Chronic lymphocytic leukemia cells with allelic deletions at 13q14 commonly have one intact RB1 gene: evidence for a role of an adjacent locus. Proc Natl Acad Sci USA 1993; 90: 8697-8701.
69. Stilgenbauer S, Döhner H, Bulgay-Mörschel M, Weitz S, Bentz M, Lichter P. High frequency of monoallelic retinoblastoma gene deletion in B-cell chronic lymphoid leukemia shown by interphase cytogenetics. Blood 1993; 81: 2118-2124.
70. Hawthorn LA, Chapman R, Oscier D, Cowell JK. The consistent 13q14 translocation breakpoint seen in chronic B-cell leukaemia (B-CLL) involves deletion of the D13S25 locus which lies distal to the retinoblastoma predisposition gene. Oncogene 1993; 8: 1415-1419.
71. Liu Y, Hermanson M, Grandér D et al. 13q deletions in lymphoid malignancies. Blood 1995; 86: 1911-1915.
72. Gardiner AC, Corcoran MM, Oscier DG. Different region of loss from chromosome 13q14 translocation in B CLL determined by FISH using Yac probes. Br J Haematol 1996; 92 (suppl 1): 80.
73. Garcia-Marco J, Jones D, Coman S et al. Lineage restriction of trisomy 12 and Rb1 deletions in chronic lymphocytic leukemia (CLL) by combined immunophenotyping and dual color interphase FISH. Blood 1995; 86 (suppl 1) 344a.
74. Mould S, Gardiner A, Corcoran M, Oscier DG. Trisomy 12 and structural abnormalities of 13q14 occurring in the same clone in chronic lymphocytic leukaemia. Br J Haematol 1996, 92: 389-392.
75. Oscier DG, Thomset A, Zhu D, Stevenson FK. Different roles of somatic hypermutation in VH genes among subsets of chronic lymphocytic leukaemia defined by chromosome abnormalities. Blood 1997, in press.
76. Dohner H, Stilgenbauer P, Liebisch A et al. 11q deletions are the second most common chromosome aberration in B-cell chronic lymphocytic leukemia and are associated with advanced stage and marked lymphadenopathy. Blood 1995; 86 (suppl 1): 345a.
77. Cuneo A, Balboni M, Piva N et al. Atypical chronic lymphocytic leukaemia with t(11;14)(q13;q32): karyotype evolution and prolymphocytic transformation. Br J Haematol 1995; 90: 409-416.
78. Dyer MJS, Zani VJ, Lu WZ et al. BCL2 translocations in leukemias of mature B cells. Blood 1994; 83: 3682-3688.
79. Merup M, Spasokoukotskaja T, Einhorn S, Smith CIE, Gahrton G, Juliusson G. Bcl-2 rearrangements with breakpoints in both vcr and mbr in non-Hodgkin's lymphomas and chronic lymphocytic leukaemia. Br J Haematol 1996; 92: 647-652.
80. Michaux L, Mecueci C, Stul M et al. BCL3 rearrangement and t(14;19)(q32;q13) in lymphoproliferative disorders. Genes, Chromosomes & Cancer 1996; 15: 38-47.
81. Fenaux P, Preudhomme C, Luc J et al. Mutations of the p53 gene in B-cell chronic lymphocytic leukemia: a report on 39 cases with cytogenetic analysis. Leukemia 1992; 6: 246-250.
82. El Roulby S, Thomas A, Costin D et al. p53 gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDR1/MDR3 gene expression. Blood 1993, 82: 3452-3459.
83. Döhner H, Fischer K, Bentz M et al. p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood 1995; 85: 1580-1589.
84. Watanabe T, Hotta T, Ichikawa A et al. The MDM2 oncogene overexpression in chronic lymphocytic leukemia and low-grade lymphoma of B-cell origin. Blood 1994; 84: 3158-3165.
85. Bournsell L, Coppin H, Pham D et al. An antigen shared by a human T cell subset and B cell chronic lymphocytic leukemia cells. J Exp Med 1980; 152: 229-234.
86. Barclay AN, Binkeland ML, Brown MH et al. The Leucocyte Antigen Facts Blood. London: Academic Press, 1993.
87. Freeman M. An ancient highly conseved family of cysteinerich proteine domains revealed by cloning type I and type II murine macrophage scavenger receptors. Proc Natl Acad Sci USA 1990; 87: 8810-8814.
88. Van de Velde H, von Hoegen I, Luo W, Parnes J, Thielemans K. The B cell surface protein CD72/Lyb-2 is the ligand for CD5. Nature 1991; 351: 662-665.
89. Caligaris-Cappio F, Gobbi M, Bofill M, Janossy G. Infrequent normal B lymphocytes express features of B chronic lymphocytic leukaemia. J Exp Med 1982; 155: 623-627.
90. Caligaris-Cappio F. B-chronic lymphocytic leukaemia: a malignancy of anti-self B cells. Blood 1996; 87: 2615-2620.
91. Vandenberghe E. Mantle cell lymphoma. Blood Reviews 1994; 8: 79-87.
92. Antin JH, Emerson SP, Martin P, Gaddol N, Ault KA. Leu 1 (CD5) B cells, a major lymphoid sub-population in human fetal spleen: phenotypic and functional studies. J Immunol 1986; 136: 505-510.
93. Kipps TJ. The CD5 B cell. Adv Immunol 1989; 47: 117-185.
94. Caligaris-Cappio F, Janossy G. Surface markers on chronic lymphoid leukemias of B cell type. Semin Hematol 1985; 22: 1-12.
95. Antin JH, Ault KA, Rappeport JM, Smith BR. B lymphocyte reconstitution after human bone marrow transplantation. J Clin Invest 1987; 80: 325-332.
96. Plater-Zyberk C, Maini RN, Lam K, Kennedy D, Janossy G. A rheumatoid arthritis B cell subset expresses a phenotype similar to that in chronic lymphocytic leukemia. Arthr Rheum 1985; 28: 971-976.
97. Manohar V, Brown E, Leiserson WM, Chused TM. Expression of Ly-1 by a subset of B lymphocytes. J Immunol 1982; 129: 532-538.
98. Herzenberg LA, Stall AM, Lalor PA, Sidman C, Moore WA, Pards DR. The Ly1-B cell lineage. Immunol Rev 1986; 93: 81-102.
99. Hayakawa K, Hardy RR, Herzenberg LA. Peritoneal Ly1-B cells: genetic control, autoantibody production, increased lambda light chain expression. Eur J Immunol 1986; 16: 450-456.
100. Hayakawa K, Hardy RR, Herzenberg LA. Progenitors for Ly1-B cells are distinct from progenitors for other B cells. J Exp Med 1985; 161: 1554-1568.
101. Mercolino TJ, Locke AL, Afshari A et al. Restricted immunoglobulin variable gene usage by normal Ly-1 (CD5+) B cells that recognise phosphatidyl choline. J Exp Med 1989; 169: 1869-1877.
102. Broker BM, Klajman A, Youinan P et al. Chronic lymphocytic leukemic (CLL) cells secrete multispecific autoantibodies. J Autoimmun 1988; 1: 469-481.
103. Dighiero G. Relevance of murine models in elucidating the origin of B-CLL lymphocytes and related immune associated phenomena. Semin Hematol 1987; 24: 240-251.
104. Dighiero G, Poncet P, Rouyre S, Mazie JC. Newborn Xia mice carry the genetic information for the production of natural autoantibodies. J Immunol 1986; 136: 4000-4005.
105. Kaushik A, Meyer R, Fidanza V, Lim A, Bona C, Dighiero G. Ly1 and V gene expression among hybridomas secreting natural autoantibody. J Autoimmun 1991; 3: 687-700.
106. Miller RA, Gralow J. The induction of Leu-1 antigen expression in human malignant and normal B cells by phorbolmyristic acetate (PMA). J Immunol 1984; 133: 3408-3412.
107. Cook GP, Tomlinson IM. The human immunoglobulin VH repertoire. Immunology Today 1995; 16: 237-242.
108. Kipps TJ, Tomhave E, Pratt LF, Duffy S, Chen PP, Carson DA. Developmental restricted VH gene expressed at high frequency in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 1989; 86: 5913-5917.
109. Schroeder HW Jr, Dighiero G. The pathogenesis of chronic lymphocytic leukemia: analysis of the antibody repertoire. Immunology Today 1994, 15: 288-294.
110. Cai J, Humphries C, Richardson A, Tucker PW. Extensive and selective mutation of a rearranged VH5 gene in human B cell chronic lymphocytic leukemia. J Exp Med 1992; 176: 1073-1081.
111. Kipps TJ, Tomhave E, Chen PP, Carson DA. Autoantibody associated kappa light chain variable region gene expressed in chronic lymphocytic leukemia with little or no somatic mutation. Implications for etiology and immunotherapy. J Exp Med 1988; 167: 840-852.
112. Pascual VK, Victor K, Spellerberg M, Hamblin TJ, Stevenson FK, Capra D. VH restriction among human cold agglutinins: the VH4-21 gene segment is required to encode anti-I and anti-i specificities. J Immunol 1992, 149: 2337-2344.
113. Kipps TJ. Implications of anti-idiotype antibodies. In Cheson BD, ed. Chronic Lymphocytic Leukaemia - Scientific Advances and Clinical Developments. New York: Marcel Dekker, 1993: 123-146.
114. Schroeder HW Jr, Hillson JL, Perlmutter RM. Early restriction of the human antibody repertoire. Science 1987, 238: 791-793.
115. Kipps TJ, Robbins BA, Carson DA. Uniform high frequency expression of autoantibody associated cross reactive idiotypes in the primary B cell follicles in human fetal spleen. J Exp Med 1990, 171: 189-196.
116. Zhu D, Hawkins R, Hamblin TJ, Stevenson FK. Clonal history of a human follicular lymphoma revealed in the immunoglobulin variable region genes. Br J Haematol 1994, 86: 505-512.
117. Goodnow CC, Crosbie J, Adelstein S et al. Altered immunoglobulin expression and functional silencing of self reactive B lymphocytes in transgenic mice. Nature 1988; 334: 676-682.
118. Cooke MD, Heath AW, Shokat AM et al. Immunoglobulin signal transduction guides the specificity of B cell-T cell interactions and is blocked in tolerant self reactive B cells. J Exp Med 1994; 179: 425-438.
119. Eris JM, Basten A, Brink R et al. Anergic self reactive B-cells present self antigens and respond normally to CD40-dependent T-cell signals but are defective in antigen-receptor mediated functions. Proc Natl Acad Sci USA 1994; 91: 4392-4396.
120. Ghigo D, Gaidano GL, Treves S et al. Na+/H+ antiporter has different properties in human B lymphocytes according to CD5 expression and malignant phenotype. Eur J Immunol 1991; 21: 583-588.
121. Michel F, Merle Beral H, Legac E, Michel A, Debre P, Bismuth G. Defective calcium response in B chronic lymphocytic leukemia cells. J Immunol 1993; 150: 3624-3633.
122. Schena M, Larrsson LG, Gottardi D et al. Growth and differentiation associated expression of Bcl-2 in B chronic lymphocytic leukemia cells. Blood 1992; 79: 2981-2989.
123. Mapara MY, Bargon R, Zugck C et al. APO-1 mediated apoptosis or proliferation in chronic B lymphocytic leukemia: correlation with Bcl-2 oncogene expression. Eur J Immunol 1993; 23: 702-708.